# Safety and Immunogenicity of Adjuvanted Reduced Dose Inactivated Polio Vaccine Given at 6, 10, 14 Weeks and 9 Months

> **NCT03032419** · PHASE3 · COMPLETED · sponsor: **Statens Serum Institut** · enrollment: 1002 (actual)

## Conditions studied

- Poliomyelitis

## Interventions

- **BIOLOGICAL:** IPV-Al SSI
- **BIOLOGICAL:** IPV SSI

## Key facts

- **NCT ID:** NCT03032419
- **Lead sponsor:** Statens Serum Institut
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-02-06
- **Primary completion:** 2017-09-21
- **Final completion:** 2018-03-12
- **Target enrollment:** 1002 (ACTUAL)
- **Last updated:** 2018-11-14

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03032419

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03032419, "Safety and Immunogenicity of Adjuvanted Reduced Dose Inactivated Polio Vaccine Given at 6, 10, 14 Weeks and 9 Months". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT03032419. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*